Radiation/nuclear medical countermeasure product development support
Award Notice Posted
- Solicitation number
- 75N93020D00011
- Agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Awarded
- to Sri International
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75N93020D00011 Federal IDV award
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Place of performance
- Menlo Park CA 94025 USA
Notice details come from SAM.gov. Updated .
About this opportunity
The National Institute of Allergy and Infectious Diseases has awarded an IDIQ contract to SRI International to provide radiation/nuclear medical countermeasure product development support. Under this contract, SRI International will advance candidate medical countermeasures toward FDA approval or licensure for acute radiation syndrome and delayed effects of acute radiation exposure through research and development studies. Candidate countermeasures will enter the evaluation and development pathway at various stages. The contract has a value of $24,180,221 and was awarded on June 30, 2020.
Notice text
The National Institute of Allergy and Infectious Diseases has awarded an IDIQ contract titled “Radiation/Nuclear Medical Countermeasure Product Development Support” to advance the development of candidate medical countermeasures (MCMs), including biodosimetric approaches to determine radiation exposure. Research and development studies supported by this contract will advance candidate MCMs toward eventual FDA approval or licensure for acute radiation syndrome (ARS) or delayed effects of acute radiation exposure (DEARE).
Candidate MCMs will enter the evaluation and development pathway at various stages, from early research to post marketing (for drugs or biologics that are already licensed or approved for other indications). The Contractor will collaborate with NIAID and, under the direction of NIAID, with organizations that have developed MCMs and with other federal authorities, including the Food and Drug Administration (FDA).
Awarded contract 75N93020D00011 to SRI International for 24180221.00 on 2020-06-30.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity